These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1653660)

  • 1. Fasting and post-prandial splanchnic blood flow is reduced by a somatostatin analogue (octreotide) in man.
    Cooper AM; Braatvedt GD; Qamar MI; Brown H; Thomas DM; Halliwell M; Read AE; Corrall RJ
    Clin Sci (Lond); 1991 Aug; 81(2):169-75. PubMed ID: 1653660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Splanchnic hemodynamic effects of somatostatin and octreotide in cirrhotic patients. A Doppler ultrasonographic study].
    Fernández Pérez FJ; Jiménez Sáenz M; García Montes JM; Rebollo Bernárdez J; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 2008 Sep; 100(9):552-9. PubMed ID: 19025306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term haemodynamic effects of octreotide on postprandial splanchnic hyperemia in humans: a placebo-controlled echo-doppler study.
    Ludwig D; Terai S; Brüning A; Stange EF
    Aliment Pharmacol Ther; 1999 Aug; 13(8):1119-29. PubMed ID: 10468691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemodynamic effects of propranolol, octreotide and their combination during fasting and post-prandial splanchnic hyperaemia in patients with cirrhosis.
    Sabbà C; Buonamico P; Vendemiale G; Berardi E; Antonica G; Palmieri V; Merkel C; Palasciano G
    Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):163-9. PubMed ID: 11246616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension.
    Albillos A; Rossi I; Iborra J; Lledó JL; Calleja JL; Barrios C; García P; Escartín P
    J Hepatol; 1994 Jul; 21(1):88-94. PubMed ID: 7963427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function.
    Malesci A; Tacconi M; Valentini A; Basilico M; Lorenzano E; Salerno F
    J Hepatol; 1997 Apr; 26(4):816-25. PubMed ID: 9126794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of long-term administration of octreotide in portal vein-stenosed rats.
    Lin HC; Yang MC; Hou MC; Li SM; Huang YT; Yu PC; Tsai YT; Lee SD
    Hepatology; 1996 Mar; 23(3):537-43. PubMed ID: 8617434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short- and long-term hemodynamic response to octreotide in portal hypertensive patients: a double-blind, controlled study.
    Zironi G; Rossi C; Siringo S; Galaverni C; Gaiani S; Piscaglia F; Bolondi L
    Liver; 1996 Aug; 16(4):225-34. PubMed ID: 8877991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study.
    McCormick PA; Biagini MR; Dick R; Greenslade L; Chin J; Cardin F; Wagstaff D; McIntyre N; Burroughs AK
    Hepatology; 1992 Nov; 16(5):1180-6. PubMed ID: 1427656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide ameliorates the increase in collateral blood flow during postprandial hyperemia in portal hypertensive rats.
    Sakurabayashi S; Koh KC; Chen L; Groszmann RJ
    J Hepatol; 2002 Apr; 36(4):507-12. PubMed ID: 11943422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior mesenteric artery blood flow in man measured with intra-arterial Doppler catheters: effect of octreotide.
    McCormick PA; Seifalian AM; Stansby G; McGann G; Collins P; Chin J; McIntyre N; Dick R; Burroughs AK
    J Hepatol; 1993 Jan; 17(1):20-7. PubMed ID: 8383155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The peptide release inhibitor, Octreotide (SMS 201-995), prevents the haemodynamic changes following food ingestion in normal human subjects.
    Kooner JS; Peart WS; Mathias CJ
    Q J Exp Physiol; 1989 Jul; 74(4):569-72. PubMed ID: 2798766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of octreotide on fasting and postprandial splanchnic hemodynamics in cirrhosis.
    Nachi M; Kanazawa H; Taki Y; Narahara Y; Yoshimoto H; Nakatuka K; Sakamoto C
    Hepatol Res; 2004 Oct; 30(2):79-85. PubMed ID: 15519271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in patients with TIPS.
    Schiedermaier P; Göke B; Sauerbruch T
    Am J Gastroenterol; 2001 Jul; 96(7):2218-24. PubMed ID: 11467656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of glucose-induced hypotension by the somatostatin analogue octreotide (SMS 201-995) in chronic autonomic failure: haemodynamic and hormonal changes.
    Raimbach SJ; Cortelli P; Kooner JS; Bannister R; Bloom SR; Mathias CJ
    Clin Sci (Lond); 1989 Dec; 77(6):623-8. PubMed ID: 2691174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion.
    Sieber CC; Beglinger C; Bart S; Tschoepl M; Currie G; Larsen F; Drewe J
    Clin Pharmacol Ther; 2004 Jan; 75(1):70-9. PubMed ID: 14749693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence against a putative role for glucagon as a physiological splanchnic vasodilator in man.
    Braatvedt GD; Stanners A; Newrick PG; Halliwell M; Corrall RJ
    Clin Sci (Lond); 1993 Feb; 84(2):193-9. PubMed ID: 8095006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priority of blood flow to splanchnic organs in humans during pre- and post-meal exercise.
    Eriksen M; Waaler BA
    Acta Physiol Scand; 1994 Apr; 150(4):363-72. PubMed ID: 8036905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a new oral somatostatin analog (SDZ CO 611) on gastric emptying, mouth to cecum transit time, and pancreatic and gut hormone release in normal male subjects.
    Nelson-Piercy C; Hammond PJ; Gwilliam ME; Khandan-Nia N; Myers MJ; Ghatei MA; Bloom SR
    J Clin Endocrinol Metab; 1994 Feb; 78(2):329-36. PubMed ID: 7906279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal.
    Parkinson C; Drake WM; Roberts ME; Meeran K; Besser GM; Trainer PJ
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1797-804. PubMed ID: 11932320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.